Organization | Ev. Hospital Bethesda, Moenchengladbach

Ev. Hospital Bethesda, Moenchengladbach Report issue

Academic/Hospital Phase 1 Phase 3 Phase 4

Founded: Mönchengladbach Germany

Organization Overview

First Clinical Trial

2000

NCT02115204

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2017

Timeline

NOW

Now

Alternative names

CRS Mönchengladbach | Ev. Krankenhaus Bethesda Moenchengladbach | Psychosomatic Clinic of Bergisch Gladbach

Active Ingredients

Drugs in Phase 4 Trials (1)

acamprosate (campral) (1 trial)

Drugs in Phase 3 Trials (5)

cyclophosphamide (cytoxan) (2 trials)

docetaxel (taxotere) (2 trials)

epirubicin (ellence) (2 trials)

fluorouracil (efudex) (1 trial)

naltrexone (revia) (1 trial)

Drugs in Phase 1 Trials (2)

23-valent pneumococcal polysaccharide vaccine (pneumovax-23) (1 trial)

bioconjugate pneumococcal vaccine (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Alcoholism (Phase 4)

Breast Neoplasms (Phase 3)

Pneumonia (Phase 1)

Pneumonia, Bacterial (Phase 1)

Pneumonia, Pneumococcal (Phase 1)

Overview

Highest Phase: Phase 4
# of Trials: 4
# of Trial APIs: 8